Abstract
A microscopic mass balance approach has been developed to estimate the extent and rate of absorption for carrier-mediated compounds. For the case of the competitive inhibition in the presence of an inhibitor which shares the same carrier, the fraction dose absorbed (F) and absorption rate constant (ka) of a drug can be calculated from its concentration profile in the intestinal lumen. Absorption parameters obtained by single-pass perfusion experiments were used in the simulation of the absorption of some aminopenicillins. Predicted fractions dose absorbed and absorption rate constants of ampicillin and amoxicillin were significantly reduced in the presence of a 6-times higher molar dose of cyclacillin. The drug-drug interactions on the competitive absorption of carrier-mediated compounds were determined with regard to F and ka. Predicted decreases in F for some aminopenicillins correlated well with decreases in the urinary recovery in humans reported in the literature. Predicted decreases in the mean absorption rate constant\((\bar k_a )\) explain the delays in the time of peak plasma concentration (Tmax) reported in humans.
Similar content being viewed by others
References Cited
Amidon, G. L., Determination of intestinal wall permeabilities. In Crouthamel, W. and Sarapu, C. (Eds),Animal Models for Oral Drug Delivery in Man: In situ and in vivo Approaches, American Pharmaceutical Association, Washington, DC, 1983, pp. 1–25.
Amidon, G. L., Sinko, P. J. and Fleisher, D., Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds.Pharm. Res., 5, 651–654. (1988).
Atkins, G. L., Simulation studies on the kinetics of intestinal absorption.Biochim. Biophys. Acta, 596, 426–438 (1980).
Bergan, T., Penicillims,Antibiotics Chemother., 25, 1–122 (1978).
Iseki, K., Iemura, A., Sato, H., Sunada, K., Miyazaki, K. and Arita T., Intestinal absorption of several β-lactam antibiotics. V. Effect of amino-β-lactam analogues and dipeptides on the absorption of amino-β-lactam antibiotics.J. Pharm. Dyn. 7, 768–775 (1984).
Johnson, D. A. and Amidon, G. L., Determination of intrinsic membrane transport parameters from perfused intestine experiments: A boundary layer approach to estimating the aqueous and unbiased membrane permeabilities.J. Theor. Biol., 13, 193–106 (1988).
Oh, D.-M., Sinko, P. J. and Amidon, G. L., Predicting oral drug absorption in humans: A macroscopic mass balance approach for passive and carrier-mediated compounds, In D'Argenio, D. Z. (Ed.)Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems, Plenum Publishing Co., 1991, pp. 3–11.
Oh, D.-M., Sinko, P. J. and Amidon, G. L., Characterization of the oral absorption of several aminopenicillins: Determination of intrinsic membrane absorption parameters in the rat intestinein situ.Int. J. Pharm., 85, 181–187 (1992).
Oh, D.-M., Curl, R. L. and Amidon., G. L., Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model.Pharm. Res., 10, 264–270, (1993).
Okano, T., Inui, K., Takano, M. and Hori, R., H+ gradient-dependent transport of aminocephalosporins in rat intestinal brush-border membrane vesicles.Biochem. Pharmacol., 35, 1781–1786 (1986).
Segel, I. H.,Enzyme Kinetics, John Wiley & Sons, Inc., NY, 1975.
Sinko, P. J. and amidon, G. L., Characterization of the oral absorption of β-lactam antibiotics, II: Competitive absorption and peptide carrier specificity.J. Pharm. Sci., 78, 723–727 (1989).
Sinko, P. J., Leesman, G. D. and Amidon, G. L., Predicting fraction dose absorbed in humans using a macroscopic mass balance approach.Pharm. Res., 8, 979–988 (1991).
Sjövall, J., Alván, G. and Westerlund, D., Oral cyclacillin interacts with the absorption of oral ampicillin, amoxicillin, and bacampicillin.Eur. J. Clin. Pharmac., 29, 495–502 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oh, DM., Amidon, G.L. Prediction of drug-drug interaction during oral absorption of carrier-mediated compounds in humans. Arch. Pharm. Res. 17, 364–370 (1994). https://doi.org/10.1007/BF02974178
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02974178